TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Efficiency Study of CARTO® 3 System Guided THERMOCOOL® Catheter Ablation Versus Fluoroscopy Guided Ablation With the Pulmonary Vein Ablation Catheter® (PVAC®)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with PAF who have had two (2) symptomatic PAF episodes in the six (6) months prior to randomization, and who are selected for catheter ablation for the treatment of their AF. Additionally patients with recurrent AF with episodes up to 30 days with sinus rhythm maintained for more than one week following cardioversion and who require PVI only for the treatment of their AF (supported by the consensus statement2). At least one AF episode should be documented either on ECG, TTM, HM or telemetry strip.~* Failure of at least one AAD for PAF \[class I or III\] as evidenced by recurrent symptomatic PAF, or intolerable side effects due to the AAD.~* Signed Patient Informed Consent Form.~* Age 18 years or older.~* Able and willing to comply with all pre- and follow-up testing and requirements.~Exclusion Criteria:~* Longstanding persistent atrial fibrillation~* Patients with a history of any atrial flutter requiring ablation in the right atrium during the study procedure~* Patients in whom sinus rhythm was maintained for less than 1 week after electrical cardioversion~* Previous ablation for AF~* LA size \> 55 mm~* LVEF \< 40% (ejection fraction)~* AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause~* CABG procedure within the last six (6) months~* Awaiting cardiac transplantation or other cardiac surgery~* Documented left atrial thrombus on imaging (eg, TEE)~* Diagnosed atrial myxoma~* Women who are pregnant (by history of menstrual period or pregnancy test if the history is considered unreliable) or breastfeeding~* Acute illness or active systemic infection or sepsis~* Unstable angina~* Uncontrolled heart failure~* Myocardial infarction within the previous two (2) months~* History of blood clotting or bleeding abnormalities~* Contraindication to anticoagulation therapy (ie. heparin or warfarin)~* Life expectancy less than 12 months~* Enrollment in any other study evaluating another device or drug~* Presence of intramural thrombus, tumor or other abnormality that precludes catheter introduction or manipulation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- THERMOCOOL® group (Type: OTHER): Radiofrequency ablation to achieve PVI using the CARTO® 3 System, the THERMOCOOL® Catheter and the LASSO® Circular Mapping Catheter.
- PVAC® group (Type: ACTIVE_COMPARATOR): Radiofrequency ablation to achieve PVI using fluoroscopy and the PVAC®

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Slump Sitting X-ray of the Lumbar Spine Is Better Than Conventional Flexion View

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients above 45 years of age;~* With mechanical low back pain,~* With spondylolisthesis~* Physically able to position themselves correctly for both methods of X-rays~Exclusion Criteria:~* Previous spinal interventions~* Suspected findings for spinal malignancies, spinal trauma, and inflammatory spinal diseases~* Pregnant women

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Slump sitting (Type: EXPERIMENTAL): Slump sitting flexion of lumbar spine
- Forward bending (Type: ACTIVE_COMPARATOR): Forward erect bending of lumbar spine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vitamin C for Prevention of Urinary Tract Infections in the Spinal Cord Injured

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* spinal cord injury~* 3 or more episodes of UVI over previous 2 years~Exclusion Criteria:~* pregnancy~* age \<18~* continuous use of antibiotics, hippuric acid or crane berry juice

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 vitamin C (Type: ACTIVE_COMPARATOR): Vitamin C 1g bid
- 2 (Type: NO_INTERVENTION): Usual Care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Tumour Response to Tirapazamine During Treatment of Cervical Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed clinically visible invasive carcinoma of the cervix, either squamous cell, adenocarcinoma or a variant of these~* Patients must be enrolled in NCIC CXC.1 (phase 3 study assessing the addition of tirapazamine) and randomized to the tirapazamine arm~* No known bleeding disorder~* Willing to undergo a clinical exam to obtain tissue biopsy for hypoxia marker analysis and DNA damage assessments~Exclusion Criteria:~* Inability to give informed consent~* Criteria below for contrast MRI only :~  1. Chronic renal disease currently on dialysis~ 2. Renal insufficiency defined as a Glomerular Filtration Rate (GFR) ≤15cc/min , serum Cr \>130, or a BUN\>7 measured~ 3. Current pacemaker, tens neuro-stimulator, implanted drug infusion devices, any metal implants, foreign metals objects in eyes, aneurysm clips

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Percutaneous RVAD to Preemptively Treat Right Heart Failure Post-LVAD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 18-75~* Accepted for LVAD implantation by MGH multidisciplinary team~Exclusion Criteria:~* Disorders of the pulmonary artery wall that would preclude placement or correct positioning of RVAD~* Presence of mechanical valves~* Mural thrombosis of the right atrium or vena cava~* Anatomic conditions precluding insertion of the RVAD~* Complicated venous access precluding or complicating device placement (i.e. femoral and jugular thrombosis)~* No evidence of right ventricular dysfunction by echocardiogram

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- prospective interventional cohort (Type: EXPERIMENTAL): The prospective interventional cohort will consist of patients undergoing LVAD implantation at Massachusetts General Hospital. These patients will receive an RVAD (either the ProtekDuo or Impella RP) prior to or during LVAD implantation.
- retrospective control cohort (Type: NO_INTERVENTION): The historical control cohort will consist of retrospective data collection on patients who have undergone LVAD implantation in the past. This group will be age and sex matched with the enrolled prospective interventional patients.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2090314 and Chemotherapy in Participants With Metastatic Pancreatic Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic pancreatic cancer with metastases amenable to biopsy~* Willingness to provide tissue and blood samples for research purposes~* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1~Exclusion Criteria:~* History of islet cell, acinar cell, or cystadenocarcinomas~* Prior cytotoxic chemotherapy for metastatic disease, except prior gemcitabine or FOLFIRINOX (5FU + leucovorin + irinotecan + oxaliplatin)~* Radiation therapy, immunotherapy or biologic therapy \<28 days prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2090314 + Gemcitabine (Type: EXPERIMENTAL): LY2090314 given intravenously (IV) on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 milligram/square meter (mg/m\^2) gemcitabine given IV on days 1, 8 and 15. Cohort closed to new enrollment per protocol addendum.
- LY2090314 + FOLFOX (Type: EXPERIMENTAL): LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), and 15 in 28 day cycle in combination with FOLFOX (leucovorin + 5-fluorouracil + oxaliplatin) given IV, on days 1 and 15 in 28 day cycle.
- LY2090314 + Gemcitabine + Nab-paclitaxel (Type: EXPERIMENTAL): LY2090314 given IV on days 1 (at cycle 1 LY2090314 given on day 0 instead of day 1), 8 and 15 in 28 day cycle in combination with 1000 mg/m\^2 gemcitabine + 125 mg/m\^2 nab-paclitaxel given IV on days 1, 8 and 15 in 28-day cycle. New cohort opened per protocol amendment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sirolimus In Autosomal Dominant Polycystic Kidney Disease And Severe Renal Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years~* Clinical and ultrasound diagnosis of ADPKD~* GFR 40-15 ml/min/1.73 m2 (estimated by the 4 variable MDRD equation)~* Urinary protein excretion rate \< 0.5 g/ 24 hrs~* Written informed consent~Exclusion Criteria:~* Diabetes~* Urinary protein excretion rate \>0.5 g/ 24 hrs or abnormal urinalysis suggestive of concomitant, clinically significant glomerular disease~* Urinary tract lithiasis, infection or obstruction~* Cancer~* Psychiatric disorders and any condition that might prevent full comprehension of the purposes and risks of the study~* Pregnancy, lactation or child bearing potential and ineffective contraception (estrogen therapy in post menopausal women should not be stopped)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Sirolimus (Type: EXPERIMENTAL): None
- conventional therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Visionaire: A Prospective Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with sufficient symptoms from articular knee pathology to be an appropriate candidate for TKA~Exclusion Criteria:~* prior TKA~* ipsilateral upper tibial or distal femoral osteotomy~* ipsilateral total hip arthroplasty~* patient with significant \>15o varus or valgus~* morbid obesity or those patients unable to have an MRI based on thigh circumference (22 cm or less)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Computer-aided TKA (Type: EXPERIMENTAL): The Visionaire system is a computer-aided system utilizing MRI of the knee prior to TKA surgeries. This technology achieves accurate rotational and A-P position. All of the commonly-referred anatomical landmarks (AP axis, epicondylar axis) are analyzed pre-operatively, allowing for the proper positioning of the implant for each patient.
- Conventional TKA (Type: OTHER): A conventional TKA utilizes a jig system based on either intra-medullary or extra-medullary guides. No knee MRI is utilized for a conventional TKA.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Impact of the Nurse Visit on Observance of the Intake of Oral Carcinological Treatment in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient aged 70 and over~* Patient initiating an oral anticancer treatment (Chemotherapy, Targeted therapy, 2nd generation hormone therapy type Acetate abiraterone and Enzalutamide)~* Patient who received an onco-geriatric assessment~* Patient with informed consent signed~Exclusion Criteria:~* Patient in a medical institution~* Patient under exclusive hormone therapy~* Patient already eligible for nurse support~* Patient not speaking French~* Patient under tutelage and guardianship or under safeguard of justice~* Patient already included in a research protocol~* Patient sharing his or her home with a person receiving nursing care at home more than once a week and for a period longer than 1 month after the patient's inclusion.

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- with nursing visit (Type: EXPERIMENTAL): a nurse visit is scheduled twice a week during 3 months at patient home.
- without nursing visit (Type: EXPERIMENTAL): no nursing visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prediction of Chronic Pain by the Pain Monitor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* adult patients of both sexes~* planned pulmonary resection for cancer performed by a posterolateral thoracotomy~* thoracic epidural analgesia~Exclusion Criteria:~* pregnancy,~* morbid obesity,~* insulin-dependent diabetes with dysautonomia,~* inability to proceed with anesthesia using the BIS signal,~* known allergy to remifentanil, propofol, atracurium or to levobupivacaine,~* contra-indication to nefopam~* contra-indication to ketoprofen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Thoracotomized patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Virtual Reality Decreases Child Anxiety and Pain as Well as Caregiver Anxiety and Pain Perception During Orthopaedic Clinic Office Procedures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for pediatric patient:~* Undergoing cast removal, pin removal, or suture removal in study affiliated clinic~* Less than 17 years old~Exclusion Criteria for pediatric patient:~* History of seizures~* Pregnant, have preexisting binocular vision abnormalities or psychiatric disorders, or suffer from a heart condition or other serious medical condition~* Patients can't have implanted medical devices including cardiac pacemakers, hearing aids and defibrillators~There is no minimum or maximum age for the Caretakers/Parents.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Standard comfort given
- Virtual Reality (VR) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Manual Therapy Versus Exercise on Knee Osteoarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of knee osteoarthritis.~Exclusion Criteria:~* Inability to ambulate at least 100 feet, ride a stationary bicycle for at least 10 minutes, or lie in the prone position for at least 10 minutes,~* Intra-articular knee injection within one month of study inception,~* A history of exercise induced or uncontrolled angina within three months of the study entry,~* Severe dyspnea at rest,~* Previous bilateral total knee arthroplasty,~* Pregnancy, OR~* The absence of knee pain at the time of recruitment for the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: t

Study Arms:
- Manual Therapy (Type: EXPERIMENTAL): Subjects will receive oscillatory (grade 1 \& 2) manual knee mobilization for 15 minutes at various knee range of motion positions.
- Therapeutic Exercise (Type: EXPERIMENTAL): Subjects will perform 15 minutes of combined resistance exercise and aerobic exercise.
- Control (Type: PLACEBO_COMPARATOR): Subjects will watch a 15 minute instructional video on a health topic.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Psychotic Major Depression With Mifepristone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:Inclusion criteria for PMD (individuals with Psychotic Major Depression) are as follows:~1. DSM IV diagnosis of Major Depressive Disorder with psychotic features, Bipolar II Disorder with psychotic features in a major depressive episode.~2. 21-item HAM-D score greater than or equal to 21.~3. Thase Core Endogenomorphic Scale score greater than or equal to 6 on the items included in the 21-item HDRS.~4. Between 21 - 85 years of age.~5. Female patients of child bearing capacity with Psychotic Depression receiving treatment with mifepristone are required to use a double-barrier method of contraception or abstinence for the entire duration of the study as well as for thirty days after the last dose of Mifepristone is taken.~6. If currently taking antipsychotic, antidepressant, anticonvulsant, and/or mood-stabilizing medications, must be stable on the medication for at least one-week prior to entering the study.~7. Pre-existing (current) primary treating psychiatrist for subjects with psychotic features.~8. Any secondary diagnoses from the anxiety disorder spectrum is acceptable. Any secondary diagnoses from the anxiety disorder spectrum is acceptable. Primary pre-existing chronic Obsessive-Compulsive Disorder(OCD) will be an exclusion criteria. Exclusion Criteria:Exclusion criteria for PMDs are as follows:~1. ECT in the 6 months prior to the study. 2. Abuse of drugs or alcohol in the 6 months prior to study. 3. Unstable or untreated hypertension, cardiovascular disease. 4. If participating in the blood draw portion of the protocol, endocrine disorders are exclusionary. 5. Use of additional prescription medications, street drugs, or alcohol during the week before the study. 6. Previous mifepristone failure or non-response. 7. Any Axis II diagnosis or traits which would make participation in the study difficult. 8. Current pregnancy or lactation.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Mifepristone (Type: EXPERIMENTAL): Receive mifepristone for 8 days
- Placebo (Type: PLACEBO_COMPARATOR): Receive placebo rather than mifepristone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: DIAFAX I+II-Effects of Inhalative Anesthetics on Left Ventricular Diastolic Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* part I: 18- to 50-year-old patients undergoing surgical procedures under general anesthesia~* part II: 50-years-old patients or older with arterial hypertension under chronic antihypertensive medication subsequently undergoing surgical procedures under general anesthesia, EF \>50%~Exclusion Criteria:~* part I: any cardiac or pulmonary disease, any medication with cardiovascular effects or side effects, body mass index \> 30 kg/m2, esophageal reflux, emergency~* part II: History of myocardial infarction or coronary revascularization, severe lung disease, body mass index \> 30 kg/m2, esophageal reflux, emergency

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: ACTIVE_COMPARATOR): Isoflurane (only in part I)
- II (Type: ACTIVE_COMPARATOR): Sevoflurane
- III (Type: ACTIVE_COMPARATOR): Desflurane

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues